Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AZD5004 in Adults With Type 2 Diabetes Mellitus
2024-512562-34-00Phase 2Completed
- Sponsor
- AstraZeneca
- Start
- Nov 2024
- Modality
- Small Molecules
- Countries
- 9
01
Overview
Phase 2, randomised, double-blind trial of elecoglipron in type 2 diabetes mellitus (T2DM) (3 arms), sponsored by AstraZeneca. Primary endpoint: Change in HbA1c from baseline to 26 weeks. Started Nov 2024; status: completed.
02
Drugs
elecoglipron
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on 2024-512562-34-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-512562-34-00.